ZOSTAVAX
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Herpes Zoster
Conditions
Herpes Zoster
Trial Timeline
Jun 20, 2011 → Oct 15, 2012
NCT ID
NCT01391546About ZOSTAVAX
ZOSTAVAX is a phase 3 stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT01391546. Target conditions include Herpes Zoster.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01391546 | Phase 3 | Completed |
| NCT01328548 | Pre-clinical | Completed |
| NCT00561080 | Phase 3 | Completed |
Competing Products
20 competing products in Herpes Zoster